Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIXNASDAQ:GALTNYSE:JATTNASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.38-4.8%$2.85$2.07▼$4.20$108.87M0.34102,957 shs224,888 shsGALTGalectin Therapeutics$2.42-26.4%$1.45$0.73▼$3.90$153.17M0.54406,496 shs4.32 million shsJATTJATT Acquisition$1.13+1.8%$1.21$7.80▼$12.38$19.49MN/A41,322 shs536,763 shsPLRXPliant Therapeutics$1.28-2.3%$1.44$1.10▼$16.10$78.57M1.351.13 million shs1.20 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-4.79%+1.20%+32.03%+6.96%+36.84%GALTGalectin Therapeutics-26.44%+76.64%+89.06%+52.20%+3.86%JATTJATT Acquisition0.00%-9.02%+3.74%-20.14%-67.16%PLRXPliant Therapeutics-2.29%-7.25%-3.76%-17.42%-88.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences3.2137 of 5 stars3.65.00.00.01.73.30.0GALTGalectin Therapeutics1.6092 of 5 stars3.50.00.00.03.11.70.0JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APLRXPliant Therapeutics4.1626 of 5 stars3.04.00.04.72.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.25Buy$9.00166.27% UpsideGALTGalectin Therapeutics 3.00Buy$6.00147.93% UpsideJATTJATT Acquisition 0.00N/AN/AN/APLRXPliant Therapeutics 2.00Hold$13.31940.04% UpsideCurrent Analyst Ratings BreakdownLatest JATT, PLRX, GALT, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.006/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.004/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/2/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/26/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/21/2025ANIXAnixa BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K518.43N/AN/A$0.46 per share7.35GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/AJATTJATT AcquisitionN/AN/A$0.04 per share27.08($0.53) per shareN/APLRXPliant Therapeutics$1.58M49.73N/AN/A$5.00 per share0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.38N/A∞N/AN/A-68.17%-60.38%9/5/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/11/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/APLRXPliant Therapeutics-$210.30M-$3.61N/AN/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)Latest JATT, PLRX, GALT, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10-$0.09+$0.01-$0.09N/AN/A5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.898.89GALTGalectin TherapeuticsN/A0.080.08JATTJATT AcquisitionN/A0.150.15PLRXPliant TherapeuticsN/A11.0311.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%GALTGalectin Therapeutics11.68%JATTJATT Acquisition47.97%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%GALTGalectin Therapeutics50.10%JATTJATT Acquisition20.00%PLRXPliant Therapeutics8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.21 million24.06 millionOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionablePLRXPliant Therapeutics9061.39 million56.48 millionOptionableJATT, PLRX, GALT, and ANIX HeadlinesRecent News About These CompaniesPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of "Hold" from AnalystsJune 16, 2025 | marketbeat.comAnalysts Issue Forecasts for PLRX FY2026 EarningsJune 12, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for PLRX FY2026 EarningsJune 10, 2025 | marketbeat.comAlnylam, Pliant among stocks yet to face Q2 catalysts: Wells FargoJune 8, 2025 | msn.comBank of America Corp DE Has $1.59 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)June 5, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by AnalystsMay 24, 2025 | marketbeat.comPliant Therapeutics presents new fibrosis treatment dataMay 23, 2025 | investing.comFrazier Life Sciences Management L.P. Makes New Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 23, 2025 | marketbeat.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comBay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in valueMay 2, 2025 | msn.comPliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical TrialsMay 2, 2025 | biospace.comPliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woesMay 2, 2025 | fiercebiotech.comPliant Therapeutics Announces Strategic Realignment of Workforce and OperationsMay 1, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRXApril 25, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 24, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 23, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJATT, PLRX, GALT, and ANIX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.38 -0.17 (-4.79%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.62 +0.25 (+7.25%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Galectin Therapeutics NASDAQ:GALT$2.42 -0.87 (-26.44%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.41 -0.01 (-0.41%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.JATT Acquisition NYSE:JATT$1.13 +0.02 (+1.80%) As of 06/20/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Pliant Therapeutics NASDAQ:PLRX$1.28 -0.03 (-2.29%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.30 +0.02 (+1.56%) As of 06/20/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
